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Pffect of Caffeine on Ischemia
etection by Adenosine Single-Photon
mission Computed Tomography Perfusion Imaging
ilbert J. Zoghbi, MD, FACC,*† Thien Htay, MD,‡ Raed Aqel, MD, FACC,*† Linda Blackmon, RN,*
aekyeong Heo, MD, FACC,* Ami E. Iskandrian, MD, FACC, FAHA*
irmingham, Alabama; and Los Angeles, California
OBJECTIVES The purpose of this research was to study the effect of one cup of coffee taken 1 h before
adenosine stress on the results of myocardial perfusion imaging.
BACKGROUND Caffeine is believed to attenuate the coronary hyperemic response to adenosine by competitive
blockade of the A2a receptor. Caffeine is commonly withheld before adenosine single-photon
emission computed tomography (SPECT) perfusion imaging so as not to mask ischemia
detection.
METHODS We studied the effect of one 8-oz cup of coffee taken 1 h before adenosine stress in patients
who had demonstrable reversible defects on adenosine SPECT perfusion imaging performed
while off caffeine.
RESULTS There were 22 men and 8 women, age 64  9 years. The blood level of caffeine 1 h after
intake was 3.1  1.6 mg/l. There were two patients with ST-segment depression before and
one after caffeine intake (p  NS). The summed stress score (SSS) based on 17 segments
(scale of 0 to 3, 3 being normal) was 44  5 before and 45  5 after caffeine (p  NS). The
summed difference score was 3.8  1.9 before and. 3.9  2.3 after caffeine (p  NS),
reflecting that around 50% of the perfusion abnormality was reversible before and after
caffeine. Using polar maps, the perfusion abnormality was 12  10% at baseline and 12 
10% after caffeine (p  NS) in agreement with SSS. The left ventricular ejection fraction by
gated SPECT was 50  13% at baseline and 51  13 % after caffeine (p  NS).
CONCLUSIONS A cup of coffee does not mask the presence or severity of reversible defects induced by
adenosine SPECT imaging. (J Am Coll Cardiol 2006;47:2296–302) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.088American College of Cardiology Foundation
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pproximately 50% of the 2.4 million pharmacological
ingle-photon emission computed tomography (SPECT)
erfusion tests performed each year in the U.S. are done
ith adenosine (1). It is generally accepted that caffeine
owers the sensitivity of adenosine SPECT by masking
yocardial ischemia because it is a nonselective competitive
nhibitor of A2 receptors (2). Activation of these receptors
y adenosine and dipyridamole results in augmentation of
yocardial blood flow (MBF). The guidelines of the Amer-
can Society of Nuclear Cardiology consider the use of
affeine within 12 h of pharmacologic vasodilator perfusion
maging as an absolute contraindication to performing the
est (3). Additionally, task force guidelines from the Amer-
can Society of Nuclear Cardiology, American Heart Asso-
iation, and American College of Cardiology recommend
bstinence from caffeine for 24 h before vasodilator SPECT
erfusion imaging (4). These recommendations stem from a
ew false-negative dipyridamole myocardial perfusion imag-
ng results in the presence of caffeine (5,6). However, there
From the *Division of Cardiovascular Disease, University of Alabama at Birming-
am, Birmingham, Alabama; †Birmingham Veterans Affairs Medical Center,
irmingham, Alabama; and the ‡University of Southern California, Los Angeles,
alifornia. Supported in part by grants from the American Society of Nuclear
ardiology/GE Award for Clinical Research in Nuclear Cardiology and Astellas
harma, USA. Dr. Iskandrian is consultant to CV Therapeutics and Astellas
orporation and received grant support from both.s
Manuscript received August 14, 2005; revised manuscript received November 2,
005, accepted November 8, 2005.re no data regarding the effects of caffeine on adenosine
yocardial perfusion imaging. Based on the assumptions
hat: 1) the nature of the interaction between adenosine and
affeine is a competitive one; 2) most patients are likely to
onsume inadvertently one cup of coffee before the scheduled
est; 3) the blood level of caffeine from such use is likely to be
ow; and 4) there is a higher interstitial level of adenosine after
denosine than dipyridamole use, we hypothesized that results
rom dipyridamole should not be extrapolated to adenosine
se. This issue of interaction between caffeine and adenosine is
linically relevant because patients are denied vasodilator im-
ging and have their studies cancelled or switched to dobut-
mine stress testing if they had consumed coffee before testing.
herefore, we attempted to study the effect of caffeine on
denosine SPECT perfusion imaging.
ETHODS
tudy population. The study included 30 patients with
nown or high likelihood of coronary artery disease who
nderwent adenosine gated SPECT perfusion imaging for
linical indications and who had evidence of reversible
efects in one or more vascular territory. Patients with prior
yocardial infarction (3 months), prior percutaneous
oronary intervention, prior coronary bypass grafting, or
atients with an abnormal coronary angiogram showing
50% stenosis in one or more vessels were included in thetudy. Patients with unstable angina, known severe left main
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June 6, 2006:2296–302 Effect of Caffeine on Adenosine SPECTtenosis, active bronchospasm, severe heart failure, un-
ontrolled arrhythmias, symptomatic hypotension or se-
ere hypertension (systolic blood pressure 90 or 200
m Hg, respectively), high-degree atrioventricular block
n the absence of a functioning pacemaker, and those on
heophylline-containing medications were excluded from
he study.
tudy design. The second adenosine gated SPECT perfu-
ion imaging (study test) was performed after the patients
rank an 8-oz cup of brewed caffeinated coffee 1 h before
denosine stress. The stress modality in both studies was
denosine only, without augmentation with low level of
xercise. There was no intervention between the first and
econd studies and no change in clinical status or medica-
ions. All patients drank the same kind and quantity of
offee, which was prepared by the cafeteria at the University
f Alabama at Birmingham. Blood caffeine levels were
rawn 1 h after coffee ingestion. Patients abstained from
affeine for 24 h before each test, and the same SPECT
rotocol (1-day rest/stress or stress/rest or 2-day protocol)
nd same tracer were used in both studies. A 6-min infusion
f 140 g/kg/min of adenosine was performed. Tc-99m
estamibi or Tc-99m tetrofosmin was injected at the third
inute of infusion. Image acquisition was done approxi-
ately 60 min after injection using a dual-head gamma
amera according to accepted standards (7). The institu-
ional review board approved the study protocol, and in-
ormed consent was obtained from each patient before
nrollment. There were no complications.
PECT interpretation. The images were coded so that
he interpreters were blinded regarding the sequence of
tudies. The two studies, without and with caffeine, were
ead blindly side by side. The interpretation addressed
resence, severity, and extent of abnormality. The summed
tress score (SSS) based on 17 segments (scale of 0 to 3,
here 3 is normal and 0 is absent perfusion) and the
ummed rest score (SRS), which reflect the total perfusion
efect at stress and rest respectively, were determined. The
ummed difference score (SDS), which reflects reversible
efects, was determined as the difference between SSS and
RS. Quantitative analysis of total defect size was per-
ormed with the polar maps using Quantitative Perfusion
PECT (Cedars-Sinai Quantitative Software Package, Los
ngeles, California). The left ventricular ejection fraction
Abbreviations and Acronyms
ATP  adenosine triphosphate
CFR  coronary flow velocity ratio
MBF  myocardial blood flow
SDS  summed difference score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress scoreas measured from the gated images. Vtatistical analysis. Statistical analysis was performed us-
ng SAS version 8.1 for Windows (SAS Institute Inc., Cary,
orth Carolina) and the SPSS software (version 10.05.5,
PSS Inc., Chicago, Illinois). Results are expressed as
ercent frequency or mean  1 SD where appropriate.
ategorical variables were assessed by a chi-square test and
ontinuous variables by a paired Student t test. Correlations
ere measured using a Pearson coefficient and the Bland-
ltman plots. A p value 0.05 (two-tailed) was considered
tatistically significant. It was estimated that a sample size of
0 patients would provide 80% power to detect a total defect
ize reduction of approximately 1.2% using a one-sided test
t the 5% significance level or two-sided test at the 2.5%
ignificance level. A 95% t-distribution-based confidence
nterval for the mean within-patient difference is 0.23 
.92%.
ESULTS
he baseline characteristics are listed in Table 1. All
atients had coronary artery disease by history of prior
yocardial infarction, history of revascularization, or 1
oronary artery with 50 stenosis. None of the eight
omen aged 48 to 76 years was on hormone replacement
herapy. None of the patients had a history of liver disease. The
aily and weekly caffeine consumptions are listed in Table 2.
erum caffeine levels were available for 29 patients. The mean
affeine level was 3.1  1.6 mg/l (range 1 to 7 mg/l), and
0% of patients had caffeine levels from 1 to 3 mg/l (Fig. 1).
able 1. Baseline Characteristics (n  30 Patients)
emographics
White 25 (83)
Male 22 (73)
Age (yrs) 64  9
Weight (lbs) 209  39
Height (inches) 69  3
edical history
Hypertension 26 (87)
Diabetes mellitus 19 (63)
Dyslipidemia 26 (87)
Active smoker 7 (23)
Peripheral vascular disease 5 (17)
Prior myocardial infarction 18 (60)
Prior coronary artery bypass grafting 16 (53)
Prior percutaneous coronary intervention 18 (60)
Pacemaker 3 (10)
Left bundle branch block 1 (3)
Referral diagnosis
Chest pains 20 (67)
Preoperative 2 (7)
Congestive heart failure 8 (27)
edications
Beta-blockers 25 (83)
Calcium blockers 5 (17)
Nitrates 15 (50)
Angiotensin-converting enzyme inhibitor 15 (50)
Angiotensin receptor blocker 8 (27)
Lipid lowering 24 (80)
Theophylline 0 (0)alues are n (%) or mean  SD.
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Effect of Caffeine on Adenosine SPECT June 6, 2006:2296–302wenty patients underwent one-day stress/rest SPECT
maging, and 10 patients underwent two-day stress/rest
PECT imaging. The SPECT and stress results are listed
n Table 3. The perfusion results by vascular territory are
isted in Table 4. Ischemia alone was present in 14 patients,
hereas 16 patients had a combination of ischemia and scar.
ingle-vessel ischemia was present in 20 patients, two-vessel
schemia in 9 patients, and three-vessel ischemia in 1
atient. The mean left ventricular ejection fraction was 50
4% on baseline study and 51  13% after caffeine
p  0.7). There were no significant differences in the SSS,
DS, and quantitative defect size with and without caffeine
Table 5). Using SSS, the percent left ventricular abnormal-
ty (SSS divided by 51) was 13.7% at baseline and 11.8%
fter caffeine (p  NS). Reversible defects (SDS) accounted
or 54% at baseline and 65% after caffeine of total abnor-
ality (p  NS). The scatter plots of the SDS and percent
otal defect size with and without caffeine are shown in
igures 2 and 3. There was no difference in the defect size
ith and without caffeine stratified by caffeine blood levels
Fig. 4). There was no conversion of a positive to a negative
tudy after intake of caffeine. A representative example of
PECT images is shown in Figure 5. Among the 14
atients who had reversible defects only, the quantitative
otal defect size was 7.1  3.2% at baseline and 7.4  4.1%
fter caffeine (p  NS). Appendix 1 shows the details of
erfusion defect distribution by vascular territories for the
0 patients. The defect size by SSS agreed nicely with defect
ize measured by the polar maps, which was 12  10% at
aseline and 12  10% after caffeine (p  NS).
ISCUSSION
he main finding of our study is that one 8-oz cup of coffee
h before adenosine stress did not attenuate the extent and
able 2. Daily Caffeine Consumption
Mean Cups Median (Range)
offee 2.0  2.2 1 (0–12)
ea 1.5  1.6 1 (0–6)
ola 1.2  1.4 1 (0–4)
esults are mean  SD.Figure 1. Distribution of caffeine levels among 29 patients.
a
weverity of reversible defects by adenosine SPECT myocar-
ial perfusion imaging. This finding was consistent across
he different caffeine blood levels, although 60% of patients
ad a caffeine level of 3 mg/l.
affeine properties. Caffeine, a methylxanthine, is present
n coffee, tea, soda, and chocolate (1). The caffeine content
er 8-oz cup of coffee varies from 25 mg to 240 mg
epending on the type of coffee and brewing method.
affeine is completely absorbed from the gastrointestinal
ract and is metabolized in the liver via the cytochrome
450 system. Its half-life is 2.5 to 4.5 h but can be as long
s 12 h, although its metabolism is fairly uniform in the
ame individual (8,9). Cytochrome P450-inducing drugs
nd smoking tend to decrease the half-life of caffeine,
hereas pregnancy, oral contraceptive drugs, cimetidine,
nd alcohol-induced liver disease tend to increase its half-
ife (1,8). The peak caffeine levels after 100 mg of oral
affeine range from 0.5 to 3.0 mg/l and are achieved within
5 to 120 min after consumption (8–10). In a study of 70
atients who were scheduled for pharmacologic myocardial
erfusion imaging and who abstained from caffeine for 12 h,
4% of patients had caffeine levels from 0.1 to 8.8 mg/l and
alf had levels 1 mg/l (11). In another study in which 86
able 3. SPECT and Stress Characteristics Without and
ith Caffeine
Without
Caffeine
With
Caffeine p Value
racer dosages
1-day rest dose (mCi) 33.6  3.0 32.0  3.0 0.1
1-day stress dose (mCi) 11.1  1.3 11.2  1.4 0.7
2-day rest dose (mCi) 35.0  3.6 36.9  4.2 0.2
2-day stress dose (mCi) 35.7  3.6 34.3  8.9 0.7
tress and hemodynamic results
ECG positive 2 (6.7) 1 (3.3) 0.4
AV block (second degree) 0 (0) 1 (3.3) 0.7
Systolic BP decrease by
10 mm Hg
21 (70.0) 21 (70.0) 0.8
Decrease in systolic BP
(mm Hg)
20.7  16.6 14.8  15.6 0.1
Increase in heart rate
(beats/min)
14.1  9.1 13.4  9.1 0.7
alues are n (%) or mean  SD.
AV  atrioventricular; BP  blood pressure; ECG  electrocardiogram; SPECT 
ingle-photon emission computed tomography.
able 4. Site of Ischemia in Relationship to Major Vessels
Ischemia
AD only 3 (10.0)
CX only 6 (20.0)
CA only 11 (36.7)
AD/LCX 2 (6.7)
AD/RCA 1 (3.3)
CX/RCA 6 (20.0)
AD/LCX/RCA 1 (3.3)
alues are n (%). Sixteen of 30 patients also had fixed defects in the same or other
ascular territories. The anterior wall and septum were considered to represent left
nterior descending artery (LAD) territory, the inferior wall to represent right
oronary artery (RCA) territory, and the lateral wall to represent the left circumflex
rtery (LCX) territory. The apex was considered in relation to adjacent territory,
hich was abnormal.
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June 6, 2006:2296–302 Effect of Caffeine on Adenosine SPECTatients abstained from caffeine for 24 h before pharmaco-
ogic myocardial perfusion imaging, 40% of patients had
affeine levels from 0.1 to 5.0 mg/l (12). Zheng et al. (13)
eported that 66% of 36 patients who abstained from
affeine for 24 h before dipyridamole myocardial perfusion
maging had detectable plasma caffeine within the range of
.1 to 0.8 mg/l.
he effects of caffeine on the cardiovascular system. Caf-
eine is a weak nonselective competitive adenosine A2
eceptor antagonist compared with theophylline (14). Caf-
eine results in a modest increase in the mean, diastolic, and
ystolic blood pressures and a decrease in heart rate (2,9,15).
t is hypothesized that caffeine affects the coronary vasomo-
or tone directly by blocking the A2 receptors and indirectly
y stimulating catecholamine release, which stimulates the
lpha-2 receptors resulting in vasoconstriction (15). In
uman studies, caffeine attenuated the dipyridamole and
denosine-induced decrease in blood pressure and the in-
rease in heart rate (2,5,6,9,13,16–18). Smits et al. (17)
howed that caffeine at a mean concentration of 5.2  0.6
g/l significantly attenuated the blood pressure and heart
ate responses of adenosine, although other investigators
howed these effects at caffeine levels as low as 1 mg/l (16).
he effects of caffeine on MBF. Bottcher et al. (15)
tudied the effect of caffeine on MBF at rest and during
ipyridamole-induced hyperemia in 12 healthy volunteers
fter one to two cups of coffee using dynamic positron
mission tomography. Caffeine levels achieved in this study
anged from 0 to 8 mg/l. Caffeine did not alter the resting
able 5. Perfusion Defect Extent and Size Without and
ith Caffeine
Without Caffeine With Caffeine p Value
SS 44.0  5.0 45.0  5.0 0.2
DS 3.8  1.9 3.9  2.3 0.8
otal defect size (%)* 12.4  10.4 12.6  10.1 0.6
Using quantitative polar maps. Values are mean  SD.
SDS  summed difference score; SSS  summed stress score.d
igure 2. Scatter plot of the summed difference score (SDS) before and
fter caffeine.BF, but caused a dose-dependant attenuation of the
ipyridamole-induced hyperemic flow velocity and the cor-
nary flow velocity reserve ratio (CFR) (3.4  0.8 without
affeine vs. 2.3 0.7 with caffeine). These effects of caffeine
ere attributed to blunting of the rate-pressure product, but
specially the heart rate response, which was inversely
elated to the plasma caffeine concentration. However, 75%
f the subjects had a flow reserve 2 despite caffeine, and
he investigators suggested that the diagnostic accuracy of
harmacologic stress testing might not be altered in the
ajority of patients who drank coffee.
In another study, Kubo et al. (19) studied the effect of
affeine intake on hyperemic MBF induced by adenosine
riphosphate (ATP) and dipyridamole using positron emis-
ion tomography in 10 healthy volunteers with and without
mg/kg of oral caffeine (approximately two to three cups of
offee). The caffeine serum levels achieved were 3.1  1.6
g/l in the ATP arm and 3.3  1.3 mg/l in the dipyri-
amole arm of the study. The MBF induced by ATP
igure 3. (A) Scatter plot of percent total defect size with (Caffeine) and
ithout (Caffeine ) caffeine. (B) Bland-Altman plot of the difference of
he percent total defect sizes between the study with caffeine (Caffeine )
nd the study without caffeine (Caffeine ) versus average percent total
efect size. The data are compatible with the hypothesis that the mean
affeine () and Caffeine () percent defect size difference is 0 (t test p
alue  0.61). For percent defect size, the empirical variance of within-
atient differences is 2.46%, which for n  30 yields a 95% confidence
nterval for the mean difference with half-width 1% (0.92%).ecreased from 3.7  0.67 ml/min/g before caffeine to
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Effect of Caffeine on Adenosine SPECT June 6, 2006:2296–302.68  0.37 ml/min/g after caffeine (p  0.0001), whereas
hat attributable to dipyridamole decreased from 3.0  0.79
l/min/g before caffeine to 1.52  0.40 ml/min/g after
affeine (p  0.0001).
In an animal study, the effect of caffeine on the selective
denosine receptor agonist ATL-146e was studied before
nd after 5 mg/kg of intravenous caffeine was administered
o 19 anesthetized open-chest dogs. In this study, the
TL-146e–induced CFR decreased from 3.5 0.4 without
affeine to 2.0  0.3 with caffeine (p  0.05) (20).
In a study of 10 patients, the fractional flow reserve
nduced by intracoronary adenosine administration was
etermined before and after 5 min of 4 mg/kg intravenous
affeine. At a serum caffeine level of 3.7  1.8 mg/l, there
as no difference in the fractional flow reserve compared
ith no caffeine (0.75  0.14 vs. 76  0.13, respectively,
 0.7) (21).
he effects of caffeine on myocardial perfusion imaging. A
ase report by Smits et al. (5) showed that 4 mg/kg of
affeine infused 30 min before a dipyridamole thallium
lanar study (caffeine level of 8.8 mg/l) attenuated the
schemic electrocardiographic and the myocardial perfusion
efects that were seen when the study was performed after
6 h of caffeine abstinence. In a subsequent study of eight
atients, Smits et al. (6) showed that caffeine at an intrave-
ous dose of 4 mg/kg with an achieved plasma concentra-
igure 4. Perfusion defect size before (top panel) and after (bottom panel)
affeine stratified by caffeine levels.ion of 9.7  3.7 mg/l reversed ST-segment changes and ohest pain in four patients and attenuated perfusion defects
n 75% of the patients. In a study of 86 patients who
nderwent vasodilator myocardial perfusion imaging after
4 h of abstinence from caffeine, the frequency of thallium
edistribution was similar among patients with caffeine
evels of 0 mg/l, 0.1 to 0.9 mg/l, and 1 mg/l (12). Heller
t al. (22) studied the effects of intravenous theophylline on
denosine thallium-201 imaging in 16 patients. Theophyl-
ine significantly attenuated the adenosine-induced increase
n heart rate, side effects, and ischemic electrocardiographic
hanges. However, despite the fact that theophylline is a
tronger A2 receptor antagonist than caffeine (23), the size
f the perfusion abnormality was unchanged with and
ithout theophylline using segmental analysis or a comput-
rized score (22).
It has been suggested that a caffeine level of 2 to 2.9 mg/l
hould be the lower limit for a false-negative dipyridamole
yocardial perfusion imaging result based on the attenua-
ion effect of caffeine on dipyridamole or adenosine humoral
r side effects (11,13).
Although methylxanthines attenuate the humoral re-
ponses of adenosine and dipyridamole, the coronary vaso-
ilatory effects are independent of its systemic hemody-
amic effects. Additionally, dipyridamole and adenosine
ave different mechanisms of action and thus would interact
ifferently with caffeine. Dipyridamole acts as an indirect
2 agonist by inhibiting the facilitated adenosine reuptake
cross the cellular membranes of vascular endothelial cells,
hus increasing the concentration of endogenous adenosine
t the receptor sites (24,25). Infused adenosine, on the other
and, acts directly with the various adenosine receptors.
hus adenosine and dipyridamole have different pharmaco-
ynamic and bioavailability properties, and subsequently the
nterstitial concentration of adenosine is much higher after
denosine administration than after dipyridamole adminis-
ration. This is an important difference because caffeine is a
ompetitive inhibitor, which means that the very high
denosine interstitial concentration may overwhelm the
eceptors and continue to produce coronary hyperemia. This
ifference between adenosine and dipyridamole is seen as a
ore robust blood pressure decrease and heart rate increase
nd more defect severity and extent with adenosine com-
ared with dipyridamole (26–28). Further, even if the
egree of hyperemia is slightly reduced, it may have no
mportant impact on the results of perfusion imaging
ecause the tracer extraction levels off at flow rates above
.5-fold of the baseline flow. In the studies in which caffeine
ttenuated the dipyridamole-induced CFR, the majority of
atients had a MFR in excess of two despite caffeine
nhibition.
The results of our study are different from those of Smits
t al. (6) because adenosine was used instead of dipyridam-
le. Additionally, lower caffeine levels were achieved in our
tudy, and were one-third of those achieved in the study by
mits et al. Thus, it is reasonable to conclude that one cup
f coffee at a mean caffeine level of 3.1  1.6 mg/l does not
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June 6, 2006:2296–302 Effect of Caffeine on Adenosine SPECTttenuate the results of adenosine myocardial perfusion
maging, and therefore these patients could undergo aden-
sine SPECT imaging and the results should be clinically
eaningful.
tudy limitations. The first limitation of this study is that
t did not have a randomized crossover design. It is true that
ecause all patients underwent a no-caffeine study followed
y a prior-caffeine study, the period effect, if any, is
onfounded with the effects of prior caffeine. A crossover
esign would address this concern but might raise ethical
oncerns because results of the no-caffeine study would be
elayed for patients randomized to receive the prior caffeine
tudy first. There was no change in clinical condition and
edications between the two studies. Additionally, both
tudies were performed similarly with respect to adenosine
ose, SPECT protocol, tracer, tracer dose, and image acqui-
ition. The caffeine levels were not measured in the first or
aseline study or before ingestion of caffeine in the second or
est study. It could be that some patients had a measurable
affeine level despite abstinence for 24 h. The sample size did
ot allow further determination of a dose-response effect.
owever, our study is the largest study thus far on the effects
f caffeine on adenosine myocardial perfusion imaging. Many
igure 5. Polar map showing a perfusion defect before (Caffeine ) and a
ypertension, dyslipidemia, and a history of moderate coronary artery di
valuation of chest pain. The baseline and caffeine study showed two-ves
etween the two studies (caffeine blood level 2 mg/l). LAD  left anterio
ight coronary artery; TOT  total.approximately 50%) of our patients had fixed in addition to seversible defects. Although it would have been ideal to
elect only those with reversible defects, we were more
nterested in testing the hypothesis on a representative
roup of patients undergoing pharmacological stress testing.
urther, even in patients with fixed defects, approximately
0% of the perfusion abnormality was still reversible. Al-
hough other medications, such as nitrates, calcium channel
lockers, and beta-blockers, could have attenuated the
egree of ischemia, the patients were on the same cardiac
edications in the two studies. Thus any medication-
elated attenuation in perfusion defects would be expected
o occur in both studies and would not alter the effects of
affeine on adenosine SPECT perfusion imaging. Finally,
lthough the interpretation was blinded and sequential, the
eaders were aware that one study was with and one was
ithout caffeine. Mixing the images with images from other
atients would have been preferred. The results, however,
ere consistent with automated measurements using polar
aps.
onclusions. One cup of coffee did not attenuate the
esults of adenosine myocardial perfusion imaging. Until
urther studies become available, we believe that one cup of
offee should not be a reason to cancel a scheduled adeno-
affeine (Caffeine ). A 53-year-old white woman with diabetes mellitus,
underwent adenosine single-photon emission computed tomography for
hemia with no significant difference in extent and severity of the defect
cending coronary artery; LCX  left circumflex coronary artery; RCA fter c
sease
sel iscine study or to change to dobutamine. We continue to ask
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PPENDIX
erfusion Defect Distribution by Vascular Territories for
he Individual Patients
Patient Ischemia Scar
1 LCX/RCA LCX
2 RCA
3 RCA
4 RCA RCA
5 LCX
6 LCX RCA
7 RCA
8 LCX
9 LCX LCX/RCA
10 RCA LAD
11 RCA
12 LCX/RCA LCX
13 LCX RCA
14 RCA
15 LCX/RCA
16 RCA RCA
17 LAD
18 LAD
19 LAD/RCA
20 LCX/RCA RCA
21 RCA
22 LAD/LCX RCA
23 LAD/LCX LAD
24 LCX RCA
25 LAD/LCX/RCA LCX/RCA
26 RCA
27 LCX/RCA LAD/LCX/RCA
28 LAD LCX/RCA
29 RCA
30 LCX/RCA RCAAD  left anterior descending; LCX  left circumflex; RCA  right coronary artery.
